Cargando…

Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study

BACKGROUND: Indacaterol acetate (IND), a long-acting β(2)-agonist in combination with mometasone furoate (MF), an inhaled corticosteroid (ICS), is being explored as a once-daily (od) treatment for asthma in children. This study examined the efficacy, safety, and systemic exposure of IND 75 µg and IN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sekerel, Bulent Enis, Nell, Haylene, Laki, Istvan, Pak, Tatiana, Contreras, Edgar, Kolarz, Adam, D’Andrea, Peter, Manga, Volkan, Jain, Monish, Vaidya, Soniya, Valentin, Michele, Sen, Biswajit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514176/ https://www.ncbi.nlm.nih.gov/pubmed/37682405 http://dx.doi.org/10.1007/s40261-023-01300-8

Ejemplares similares

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
por: Miller, David, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with Asthma
por: Bartels, Christian, et al.
Publicado: (2021)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
por: Roig, Jorge, et al.
Publicado: (2009)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
por: Bleecker, Eugene R, et al.
Publicado: (2011)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects
por: Inoue, Satoru, et al.
Publicado: (2021)

Hypersensitivity Reactions to Biologicals: from Bench to Bedside
por: Akarsu, Aysegul, et al.
Publicado: (2020)

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
por: Feldman, Gregory, et al.
Publicado: (2010)

Pro and Contra: Provocation Tests in Drug Hypersensitivity
por: Soyer, Ozge, et al.
Publicado: (2017)

Allergic reactions against Covıd-19 vaccines
por: ÜNSAL, Hilal, et al.
Publicado: (2021)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
por: Woehrle, Holger, et al.
Publicado: (2023)

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use
por: Price, David, et al.
Publicado: (2013)

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
por: Siler, Thomas M, et al.
Publicado: (2014)

The many faces of pediatric urticaria
por: Sekerel, Bulent Enis, et al.
Publicado: (2023)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Fine-tuning the use of a skin prick test device
por: Kahveci, Melike, et al.
Publicado: (2020)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
por: Nishijima, Yu, et al.
Publicado: (2015)

An Expert Panel Statement on the Beneficial Effects of Human Milk Oligosaccharides (HMOs) in Early Life and Potential Utility of HMO-Supplemented Infant Formula in Cow’s Milk Protein Allergy
por: Sekerel, Bulent Enis, et al.
Publicado: (2021)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

Systematic review comparing LABA, olodaterol, and indacaterol: limitations
por: Donohue, James F
Publicado: (2014)

Clinical Validation of the Spirohome Clinic Ultrasonic Spirometer in Child and Adolescent Patients
por: Sekerel, Bulent Enis, et al.
Publicado: (2022)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
por: van Zyl-Smit, Richard N., et al.
Publicado: (2023)

A Randomized, Double-Blind, Placebo-Controlled Trial of Lessertia frutescens in Healthy Adults
por: Johnson, Quinton, et al.
Publicado: (2007)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
por: Jiang, Ji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t081g8vln5i6fe73h59mtbi2p6